2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1497

Progressive Decline of Lung Function in Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 1498

Patterns of Interstitial Lung Disease and Associated Mortality in Rheumatoid Arthritis
Abstract Number: 1499

Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis
Abstract Number: 1500

Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Abstract Number: 1501

The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Abstract Number: 1502

Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Abstract Number: 1503

Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US
Abstract Number: 1504

Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Abstract Number: 1505

Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Abstract Number: 1506

One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Abstract Number: 1507

Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Abstract Number: 1508

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Sickle Cell Patients: A Cross-Sectional Analysis
Abstract Number: 1509

Increased Fracture Risk in Patients with Early Rheumatoid Arthritis in the 1990s As Well As in the 2000s: A Prospective General Population-Matched Cohort Study
Abstract Number: 1510

Trends in the Occurrence of Malignancy in Japanese Patients with Rheumatoid Arthritis Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort during a 14-Year Observation Period
Abstract Number: 1511

Impacts of Disease Activity and Serum Level of Neurotrophic Factors on Depression in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].